Table 4.
Open in new tab

Factors associated with improvement of kidney function post adrenalectomy during 3 years of follow-up

VariablesUnivariable analysisMultivariable analysis
Estimate95% CIPEstimate95% CIP
Age (per 10-y increase)−1.05−2.48 to 0.37.146−2.79−4.69 to −0.88.004
Sex (male)1.90−2.16 to 5.95.3593.15−1.40 to 7.70.175
Body mass index (per 5-point increase)0.07−0.22 to 0.35.6470.33−1.08 to 1.75.643
Hypertension0.03−4.11 to 4.16.9900.44−4.73 to 5.61.868
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use−1.93−5.87 to 2.01.337−1.88−7.07 to 3.32.479
Dysglycemia0.35−3.60 to 4.30.862−0.67−5.30 to 3.97.777
Statin therapy−2.25−6.03 to 1.53.2422.95−7.80 to 1.91.234
Smoking2.90−1.85 to 7.65.2313.08−1.73 to 7.88.210
eGFR pre adrenalectomy−0.15−0.23 to −0.07<.001−0.27−0.38 to −0.17<.001
Follow-up time post adrenalectomy (per 1-mo increase)1.190.21 to 2.17.0171.900.81 to 2.98.001
Postdexamethasone cortisol category (>1.8 mcg/dL vs ≤ 1.8 mcg/dL)−0.57−4.98 to 3.84.800−1.15−5.86 to 3.55.631
VariablesUnivariable analysisMultivariable analysis
Estimate95% CIPEstimate95% CIP
Age (per 10-y increase)−1.05−2.48 to 0.37.146−2.79−4.69 to −0.88.004
Sex (male)1.90−2.16 to 5.95.3593.15−1.40 to 7.70.175
Body mass index (per 5-point increase)0.07−0.22 to 0.35.6470.33−1.08 to 1.75.643
Hypertension0.03−4.11 to 4.16.9900.44−4.73 to 5.61.868
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use−1.93−5.87 to 2.01.337−1.88−7.07 to 3.32.479
Dysglycemia0.35−3.60 to 4.30.862−0.67−5.30 to 3.97.777
Statin therapy−2.25−6.03 to 1.53.2422.95−7.80 to 1.91.234
Smoking2.90−1.85 to 7.65.2313.08−1.73 to 7.88.210
eGFR pre adrenalectomy−0.15−0.23 to −0.07<.001−0.27−0.38 to −0.17<.001
Follow-up time post adrenalectomy (per 1-mo increase)1.190.21 to 2.17.0171.900.81 to 2.98.001
Postdexamethasone cortisol category (>1.8 mcg/dL vs ≤ 1.8 mcg/dL)−0.57−4.98 to 3.84.800−1.15−5.86 to 3.55.631

Abbreviation: eGFR, estimated glomerular filtration rate.

Table 4.
Open in new tab

Factors associated with improvement of kidney function post adrenalectomy during 3 years of follow-up

VariablesUnivariable analysisMultivariable analysis
Estimate95% CIPEstimate95% CIP
Age (per 10-y increase)−1.05−2.48 to 0.37.146−2.79−4.69 to −0.88.004
Sex (male)1.90−2.16 to 5.95.3593.15−1.40 to 7.70.175
Body mass index (per 5-point increase)0.07−0.22 to 0.35.6470.33−1.08 to 1.75.643
Hypertension0.03−4.11 to 4.16.9900.44−4.73 to 5.61.868
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use−1.93−5.87 to 2.01.337−1.88−7.07 to 3.32.479
Dysglycemia0.35−3.60 to 4.30.862−0.67−5.30 to 3.97.777
Statin therapy−2.25−6.03 to 1.53.2422.95−7.80 to 1.91.234
Smoking2.90−1.85 to 7.65.2313.08−1.73 to 7.88.210
eGFR pre adrenalectomy−0.15−0.23 to −0.07<.001−0.27−0.38 to −0.17<.001
Follow-up time post adrenalectomy (per 1-mo increase)1.190.21 to 2.17.0171.900.81 to 2.98.001
Postdexamethasone cortisol category (>1.8 mcg/dL vs ≤ 1.8 mcg/dL)−0.57−4.98 to 3.84.800−1.15−5.86 to 3.55.631
VariablesUnivariable analysisMultivariable analysis
Estimate95% CIPEstimate95% CIP
Age (per 10-y increase)−1.05−2.48 to 0.37.146−2.79−4.69 to −0.88.004
Sex (male)1.90−2.16 to 5.95.3593.15−1.40 to 7.70.175
Body mass index (per 5-point increase)0.07−0.22 to 0.35.6470.33−1.08 to 1.75.643
Hypertension0.03−4.11 to 4.16.9900.44−4.73 to 5.61.868
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use−1.93−5.87 to 2.01.337−1.88−7.07 to 3.32.479
Dysglycemia0.35−3.60 to 4.30.862−0.67−5.30 to 3.97.777
Statin therapy−2.25−6.03 to 1.53.2422.95−7.80 to 1.91.234
Smoking2.90−1.85 to 7.65.2313.08−1.73 to 7.88.210
eGFR pre adrenalectomy−0.15−0.23 to −0.07<.001−0.27−0.38 to −0.17<.001
Follow-up time post adrenalectomy (per 1-mo increase)1.190.21 to 2.17.0171.900.81 to 2.98.001
Postdexamethasone cortisol category (>1.8 mcg/dL vs ≤ 1.8 mcg/dL)−0.57−4.98 to 3.84.800−1.15−5.86 to 3.55.631

Abbreviation: eGFR, estimated glomerular filtration rate.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close